Abstract
The discovery of key regulators of T cell response and the development of checkpoint inhibitors has led to a paradigm shift in cancer therapy. Immune checkpoint inhibitors have demonstrated remarkable tumor shrinkage and durable clinical activity. However, the clinical benefits from checkpoint inhibitors are limited to selected patients, possibly due to insufficient antitumor T cell responses and/or lack of effector T cell infiltration into tumors. Cancer vaccines with adjuvants can overcome these obstacles by inducing potent antitumor T cell responses and effector T cell infiltration into the tumor. Although preclinical data showed promising results with cancer vaccines, only a few of them have demonstrated limited success in clinical studies, likely due to weak vaccine adjuvants. Adjuvants and cytokines are essential to enhance the potency and longevity of the antitumor immunity induced by cancer vaccines. Here, we discuss current practical applications of diverse adjuvants and cytokines.
Original language | English (US) |
---|---|
Title of host publication | Immunotherapy in Translational Cancer Research |
Publisher | Wiley-Blackwell |
Pages | 115-131 |
Number of pages | 17 |
ISBN (Electronic) | 9781118684535 |
ISBN (Print) | 9781118123225 |
DOIs | |
State | Published - Apr 13 2018 |
Externally published | Yes |
Keywords
- Adjuvants
- Cytokines
- Immunotherapy
ASJC Scopus subject areas
- General Medicine